ABBV-295 (Long-Acting Amylin Analog)
AbbVie's entry into obesity, licensed from Gubra. It is notable mainly for a half-life long enough to test monthly dosing, which is rare in the amylin class.
Investigational compounds, read carefully
This section covers peptides at the frontier of research. Most entries are preclinical, in early or mid-stage clinical trials, or theoretical. Evidence levels are explicitly marked on every entry.
Nothing on these pages constitutes medical advice, dosing recommendations, or instructions for use. Many of these compounds are not commercially available; some are not legal for human use. Decisions about treatment require a qualified clinician.
At a glance
ABBV-295, previously GUB014295, is a long-acting amylin analog discovered by Gubra and licensed to AbbVie in March 2025. In the multiple-dose part of its Phase 1 trial, weekly dosing produced 7.8% to 9.8% weight loss at 12 weeks against about 0.3% on placebo. Every-other-week and monthly regimens produced 9.7% and 7.9% at week 13. Its half-life was 10.7 to 12.3 days, and nausea affected 33.3% of participants against 20.0% on placebo. A Phase 2 trial began in August 2026.
- Class
- Long-acting amylin analog
- Sponsor
- AbbVie (discovered by Gubra)
- Stage
- Phase 2 began August 2026
- Target
- Obesity; potential monthly dosing
What it is
ABBV-295 is a long-acting analog of amylin, the satiety hormone released alongside insulin. Gubra, a Danish peptide-discovery company, developed it as GUB014295 and licensed it to AbbVie in March 2025 in a deal worth up to $1.875 billion in milestones. It is AbbVie's first significant move into obesity.
The amylin class already includes cagrilintide, petrelintide, and eloralintide, all weekly. What distinguishes ABBV-295 is a half-life of about 11 to 12 days, long enough that monthly dosing is a realistic goal.
Current research status
Phase 1 results (NCT06144684) were presented at EASD on September 30, 2026. A Phase 2 trial (NCT07752979) began in August 2026. ABBV-295 is investigational and not approved anywhere.
Mechanistic rationale
Amylin signals fullness and slows stomach emptying through brain regions that only partly overlap with those GLP-1 drugs act on. That partial overlap is the basis for combining amylin and incretin drugs, as CagriSema and EloraTZP do. On its own, amylin agonism produces less weight loss than the leading incretin drugs, and early reports suggest it may be gentler on the gut.
Dosing frequency matters more than it may seem. Weekly injections are already a barrier for some people, and a monthly option would reduce it. Monthly dosing is the direction the field is moving, as covered in the shift to once-monthly dosing.
Available evidence
Why it's interesting
A monthly amylin analog would be useful on its own and as a partner for a monthly incretin drug. Weight loss of nearly 10% in 12 to 13 weeks is a solid early signal for an amylin monotherapy, and the monthly regimen did not lose much ground against weekly dosing over that short window.
It also matters as a sign of who is competing. AbbVie's entry means another large company with deep resources is now in the obesity market.
Limitations & risks
This is a Phase 1 trial with small groups, lasting only about three months. Weight loss at 12 weeks says little about where it will plateau, and the different regimens cannot be meaningfully ranked on these numbers. The results were presented at a conference and have not been peer reviewed.
Nausea in a third of participants also tempers the idea that amylin drugs are reliably easier to tolerate than incretins. Phase 2 will be the first proper look at efficacy and side effects over a longer period.
Community discussion notes
ABBV-295 has had little community attention so far, which is typical for Phase 1 assets. It is investigational and not available outside clinical trials.
Reading an early result
ABBV-295 is a credible early amylin candidate whose main distinction is a half-life that makes monthly dosing plausible. The Phase 1 numbers are encouraging for a 12-week study and say nothing yet about long-term efficacy. Phase 2 will show whether the monthly regimen holds up.
Frequently asked questions
What is ABBV-295?
A long-acting amylin analog discovered by Gubra as GUB014295 and licensed to AbbVie in 2025. It is being developed for obesity.
Could it be given monthly?
That is being tested. In Phase 1, an 8 mg monthly dose produced 7.9% weight loss at week 13, and the half-life of about 11 to 12 days supports the idea. Longer trials are needed to confirm it.
How does it compare with cagrilintide or petrelintide?
No direct comparison exists. Those drugs are dosed weekly and have larger, longer trials behind them. ABBV-295's Phase 1 results are too short and small for a meaningful cross-trial comparison.
Is ABBV-295 available?
No. It is investigational and available only in clinical trials.
References
- Gubra. Gubra's partner AbbVie presents detailed Phase 1 data for ABBV-295 at EASD 2026. September 2026. https://mfn.se/a/gubra/gubras-partner-abbvie-presents-detailed-phase-1-data-for-abbv-295-a-long-acting-amylin-analog-demonstrating-favorable-tolerability-and-pharmacokinetic-profile-at-easd-2026
- Pharmacally. ABBV-295 Phase 1 data on weight reduction at EASD 2026. 2026. https://pharmacally.com/abbv-295-phase-1-data-weight-reduction-easd-2026/